Tweenvest Stocks

Royalty Pharma plc (NasdaqGS: RPRX)

Health Care · Pharmaceuticals · US

$61.80

-0.43% today · +71.8% 1Y

Royalty Pharma plc (NasdaqGS: RPRX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $27.52B and employs 100 people.

Over the last twelve months the share price has gained 71.8%, trading between 34.08 and 61.80.

Tweenvest scores Royalty Pharma plc across four factors: quality 67/100, value 38/100, growth 27/100, dividend 75/100. Its strongest factor is dividend.

RPRX price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$27.52B
Revenue (TTM)
$2.54B
P/E
33.15
EPS
1.86
Dividend yield
1.51%
Beta (5Y)
0.43
52-week high
$61.80
52-week low
$34.08
Avg volume (3M)
Shares outstanding
445.28M
Employees
100
Next earnings

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

ISIN
GB00BMVP7Y09
Founded
1996
Listed since
Jun 16, 2020
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
Eli Lilly and CompanyNYSE: LLY$1.06T$1,189.41-3.59%
Johnson & JohnsonNYSE: JNJ$650.67B$270.00-1.15%
Merck & Co., Inc.NYSE: MRK$377.72B$153.10-2.14%
Roche Holding AGSWX: ROP$365.10BCHF368.30-1.47%
Novartis AGSWX: NOVN$300.07BCHF127.18-0.90%
AstraZeneca PLCLSE: AZN$257.89B£122.34-1.94%
Novo Nordisk A/SCPSE: NOVO B$210.23BDkr304.95-0.93%
Pfizer Inc.NYSE: PFE$161.30B$28.30-0.95%

Browse every Pharmaceuticals company →

Figures last refreshed Aug 18, 2026.